See more : Smart Powerr Corp. (CREG) Income Statement Analysis – Financial Results
Complete financial analysis of Yield10 Bioscience, Inc. (YTEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yield10 Bioscience, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- KRM22 Plc (KRMCF) Income Statement Analysis – Financial Results
- Cognizant Technology Solutions Corporation (0QZ5.L) Income Statement Analysis – Financial Results
- Power Corporation of Canada (PWCDF) Income Statement Analysis – Financial Results
- TLGY Acquisition Corporation (TLGYU) Income Statement Analysis – Financial Results
- ECSC Group plc (ECSC.L) Income Statement Analysis – Financial Results
Yield10 Bioscience, Inc. (YTEN)
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00K | 450.00K | 614.00K | 799.00K | 806.00K | 556.00K | 944.00K | 1.16M | 2.59M | 2.80M | 5.39M | 42.32M | 1.43M | 448.00K | 1.43M | 1.56M | 1.68M | 4.59M | 2.78M | 3.68M | 2.38M | 1.99M |
| Cost of Revenue | 290.00K | 656.00K | 578.00K | 5.22M | 4.85M | 4.78M | 4.60M | 5.67M | 660.00K | 1.48M | 3.03M | 1.43M | 24.45M | 23.67M | 24.47M | 24.67M | 19.90M | 11.24M | 5.98M | 5.43M | 0.00 | 0.00 |
| Gross Profit | -230.00K | -206.00K | 36.00K | -4.42M | -4.04M | -4.23M | -3.65M | -4.51M | 1.93M | 1.32M | 2.37M | 40.89M | -23.02M | -23.23M | -23.05M | -23.11M | -18.22M | -6.65M | -3.20M | -1.75M | 2.38M | 1.99M |
| Gross Profit Ratio | -383.33% | -45.78% | 5.86% | -553.32% | -501.49% | -760.25% | -386.97% | -389.21% | 74.56% | 47.07% | 43.90% | 96.63% | -1,615.44% | -5,184.15% | -1,617.26% | -1,486.30% | -1,082.47% | -144.77% | -115.04% | -47.53% | 100.00% | 100.00% |
| Research & Development | 8.32M | 7.75M | 6.20M | 5.36M | 4.85M | 4.78M | 4.60M | 5.67M | 16.57M | 17.34M | 19.13M | 23.18M | 0.00 | 0.00 | 0.00 | 24.67M | 19.90M | 11.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 3.83M | 3.25M | 0.00 | 2.64M |
| Other Expenses | 0.00 | 41.00K | -3.00K | 83.00K | 21.00K | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 25.68M | 28.15M | 32.87M | 37.29M | 15.84M | 15.71M | 15.68M | 40.45M | 35.50M | 22.11M | 3.83M | 3.25M | 0.00 | 7.05M |
| Cost & Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 26.34M | 29.63M | 35.90M | 38.71M | 40.29M | 39.39M | 40.15M | 40.45M | 35.50M | 22.11M | 9.81M | 8.68M | 0.00 | 7.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 158.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 5.94M | 1.47M | 109.36K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 13.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00K | 0.00 | 772.00K | 2.89M | 0.00 | 5.00K | 10.14K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 290.00K | 656.00K | 578.00K | 611.00K | 1.83M | 784.00K | 206.00K | 177.00K | 265.00K | 507.00K | 928.00K | 1.30M | 1.51M | 1.65M | 2.73M | 3.73M | 1.45M | 964.00K | 314.57K | 265.25K | 0.00 | 0.00 |
| EBITDA | -14.13M | -13.19M | -11.47M | -9.43M | -8.39M | -9.12M | -9.08M | -10.07M | -12.35M | -26.32M | -27.61M | 4.90M | -37.35M | -37.29M | -36.00M | -35.16M | -32.37M | -16.56M | -6.71M | -4.73M | 2.38M | -5.06M |
| EBITDA Ratio | -23,545.00% | -2,930.67% | -1,982.41% | -1,101.75% | -609.93% | -1,640.83% | -949.58% | -836.50% | -907.48% | -942.25% | -547.26% | 11.58% | -2,621.33% | -8,324.11% | -2,525.96% | -2,261.16% | -1,923.05% | -360.78% | -216.11% | -128.73% | 100.00% | -254.60% |
| Operating Income | -14.42M | -13.45M | -11.69M | -9.61M | -8.60M | -9.32M | -9.28M | -10.25M | -23.74M | -26.83M | -30.50M | 3.60M | -38.86M | -38.94M | -38.73M | -38.89M | -33.82M | -17.52M | -7.02M | -5.00M | 2.38M | -5.06M |
| Operating Income Ratio | -24,028.33% | -2,989.11% | -1,904.23% | -1,202.63% | -1,066.50% | -1,676.08% | -983.37% | -884.21% | -915.30% | -958.18% | -565.48% | 8.51% | -2,727.09% | -8,691.74% | -2,717.82% | -2,501.09% | -2,009.27% | -381.79% | -252.59% | -135.94% | 100.00% | -254.60% |
| Total Other Income/Expenses | -38.00K | 41.00K | 697.00K | -541.00K | -4.61M | 134.00K | -113.00K | -38.00K | 29.00K | 61.00K | -4.00K | 27.00K | 76.00K | 136.00K | 0.00 | 0.00 | 5.94M | 1.46M | -699.64K | 0.00 | -2.38M | 5.06M |
| Income Before Tax | -14.46M | -13.41M | -11.00M | -10.15M | -13.21M | -9.19M | -9.40M | -10.29M | -23.68M | -26.77M | -30.51M | 3.63M | -38.79M | -38.80M | 0.00 | 0.00 | -27.88M | -16.06M | -7.72M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -24,091.67% | -2,980.00% | -1,790.72% | -1,270.34% | -1,638.96% | -1,651.98% | -995.34% | -887.49% | -912.91% | -956.00% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | 0.00% | 0.00% | -1,656.27% | -349.93% | -277.76% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 156.00K | 36.00K | 56.00K | -254.00K | 104.00K | 113.00K | -1.10M | -62.00K | 2.71M | 4.00K | 0.00 | 0.00 | 0.00 | -772.00K | -2.89M | 0.00 | 0.00 | 600.79K | 54.31K | 6.64M | 5.19M |
| Net Income | -14.46M | -13.57M | -11.03M | -10.21M | -12.96M | -9.19M | -9.40M | -7.60M | -23.68M | -29.53M | -30.51M | 3.63M | -38.79M | -38.80M | -37.96M | -36.01M | -27.88M | -16.06M | -7.63M | -5.05M | -6.64M | -5.19M |
| Net Income Ratio | -24,091.67% | -3,014.67% | -1,796.58% | -1,277.35% | -1,607.44% | -1,651.98% | -995.34% | -656.08% | -912.91% | -1,054.79% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | -2,663.65% | -2,315.43% | -1,656.27% | -349.93% | -274.20% | -137.42% | -278.62% | -260.83% |
| EPS | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -149.23K | -79.89K | -158.62K | -100.88K |
| EPS Diluted | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -121.96K | -79.89K | -158.62K | -100.88K |
| Weighted Avg Shares Out | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 588.00 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 51.10 | 63.27 | 41.86 | 51.43 |
| Weighted Avg Shares Out (Dil) | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 589.07 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 62.52 | 63.27 | 41.86 | 51.43 |
Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript
Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript
Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results
-Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market -Advanced regulatory and seed scale-up program for omega-3 Camelina -E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada -Management will host a conference...
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024
WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate...
Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada
WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported that the Plant Biosafety Office (“PBO”) of the Canadian Food Inspection Agency (“CFIA”) recently reviewed information on the...
Why Is Yield10 (YTEN) Stock Up 117% Today?
Yield10 Bioscience (NASDAQ: YTEN ) stock is rocketing higher on Thursday after the agricultural bioscience company got new approval from the Department of Agriculture's (USDA) Biotechnology Regulatory Services (BRS). The big news here is Yield10 Bioscience's Camelina sativa varieties getting...
USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States
Yield10 Bioscience achieves significant milestone enabling ramp-up to commercial scale production of omega-3 fatty acids in Camelina in the United States.
Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests
-Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets -Herbicide tolerance is critical to planting the Camelina crop on large acreage for the biofuel and omega-3 oil markets
Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock
Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production Global License of Industry-Leading Elite Herbicide Tolerant Camelina Accelerates Biofuel Feedstock Production
Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program
-Prioritizes Activities to Advance Omega-3 Camelina Program in 2024 -Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile - Company also Provides Update on Nasdaq Status - WOBURN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience,...
Why Is Yield10 Bioscience (YTEN) Stock Up 34% Today?
Yield10 Bioscience (NASDAQ: YTEN ) stock is rocketing higher on Monday despite a lack of news from the U.S. agricultural bioscience company. This rally comes alongside heavy trading of YTEN stock on Monday morning.
Source: https://incomestatements.info
Category: Stock Reports